Mesoblast (MESO) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Mesoblast Limited has issued 2 million unquoted warrants as part of a US$50 million convertible note facility, which the company can utilize following FDA approval. Each warrant can convert into one ordinary share or into American Depositary Receipts at a specified exchange rate. This strategic move aims to bolster Mesoblast’s financial flexibility and potential market positioning.
For further insights into MESO stock, check out TipRanks’ Stock Analysis page.
